Overview

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

Status:
Recruiting
Trial end date:
2023-04-27
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).
Phase:
Phase 4
Details
Lead Sponsor:
Daiichi Sankyo, Inc.